Grail, Llc Stock Today
| GRAL Stock | 13.80 0.07 0.50% |
Performance0 of 100
| Odds Of DistressLess than 49
|
GRAIL, LLC is selling for 13.80 as of the 20th of September 2024. This is a 0.5 percent decrease since the beginning of the trading day. The stock's lowest day price was 13.8. GRAIL, LLC has 49 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. GRAIL, LLC symbol was changed from GRALV on 25th of June 2024. Equity ratings for GRAIL, LLC are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 1st of October 2022 and ending today, the 20th of September 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 25th of June 2024 | Category Healthcare | Classification Health Care |
GRAIL, LLC is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 31.05 M outstanding shares of which 3.21 M shares are currently shorted by private and institutional investors with about 3.81 trading days to cover. More on GRAIL, LLC
Moving together with GRAIL, Stock
Moving against GRAIL, Stock
GRAIL, Stock Highlights
| Older Symbol | GRALV | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CEO Director | Robert Ragusa | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Healthcare (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Healthcare, Health Care, Biotechnology, Diagnostics & Research, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GRAIL, LLC can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand GRAIL, LLC's financial leverage. It provides some insight into what part of GRAIL, LLC's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GRAIL, LLC (GRAL) is traded on NASDAQ Exchange in USA. It is located in 1525 O?Brien Drive, Menlo Park, CA, United States, 94025 and employs 1,360 people. GRAIL, LLC was previously known as GRAIL, Common Stock and was traded on NASDAQ Exchange under the symbol GRALV. GRAIL, LLC is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 431.89 M. GRAIL, LLC conducts business under Biotechnology sector and is part of Health Care industry. The entity has 31.05 M outstanding shares of which 3.21 M shares are currently shorted by private and institutional investors with about 3.81 trading days to cover.
GRAIL, LLC generates negative cash flow from operations
Check GRAIL, LLC Probability Of Bankruptcy
Ownership AllocationGRAIL, LLC secures a total of 31.05 Million outstanding shares. The majority of GRAIL, LLC outstanding shares are owned by institutions. These other corporate entities are usually referred to as non-private investors looking to purchase positions in GRAIL, LLC to benefit from reduced commissions. Thus, outside corporations are subject to a different set of regulations than regular investors in GRAIL, LLC. Please pay attention to any change in the institutional holdings of GRAIL, LLC as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company retains, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check GRAIL, Ownership Details
GRAIL, LLC Historical Income Statement
GRAIL, Stock Against Markets
GRAIL, LLC Corporate Management
| Paul Ciccolella | Senior Operations | Profile | |
| Amoolya Singh | Senior Officer | Profile | |
| Satnam Alag | Senior Officer | Profile | |
| Aaron Freidin | Chief Officer | Profile | |
| Julie Currie | Chief Officer | Profile | |
| MPH JD | General Counsel | Profile |
Additional Information and Resources on Investing in GRAIL, Stock
When determining whether GRAIL, LLC is a strong investment it is important to analyze GRAIL, LLC's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact GRAIL, LLC's future performance. For an informed investment choice regarding GRAIL, Stock, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GRAIL, LLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more information on how to buy GRAIL, Stock please use our How to buy in GRAIL, Stock guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GRAIL, LLC. If investors know GRAIL, will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GRAIL, LLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (87.00) | Revenue Per Share 3.534 | Quarterly Revenue Growth 0.426 |
The market value of GRAIL, LLC is measured differently than its book value, which is the value of GRAIL, that is recorded on the company's balance sheet. Investors also form their own opinion of GRAIL, LLC's value that differs from its market value or its book value, called intrinsic value, which is GRAIL, LLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GRAIL, LLC's market value can be influenced by many factors that don't directly affect GRAIL, LLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GRAIL, LLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GRAIL, LLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GRAIL, LLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.